Markets, Shares, Video

What the FDA Feedback Means for Antisense Therapeutics (ASX:ANP)

Charmaine Gittleson gives some insights into why she joined the ANP board, the way the FDA process works, and how this Type C meeting fits into clarifying the pathway to starting a clinical trial.

Published on June 4, 2021

By Staff Writers

Former Chief Medical Officer for CSL Charmaine Gittleson gives some insights into why she joined the ANP board, the way the FDA process works, and how this Type C meeting fits into clarifying the pathway to starting a clinical trial.